更新于 2020 年：非小细胞肺癌的治疗。
Update 2020: Management of Non-Small Cell Lung Cancer.
机构信息
Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
出版信息
Lung. 2020 Dec;198(6):897-907. doi: 10.1007/s00408-020-00407-5. Epub 2020 Nov 11.
Abstract
The past decade has seen a revolution of new advances in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and treatment. The advances in systemic treatment have been driven primarily by the development of molecularly targeted therapeutics, immune checkpoint inhibitors, and anti-angiogenic agents, all of which have transformed this field with significantly improved patient outcomes. This review will address updates in lung cancer screening, liquid biopsy, and immunotherapy in the front-line setting. We discuss recent advances and highlight the plethora of new approvals of molecular-targeted therapy for subgroups of NSCLC patients with sensitizing EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK alterations.
摘要
过去十年见证了非小细胞肺癌（NSCLC）管理方面的新进展，在筛查、诊断和治疗方面取得了显著的进步。系统治疗的进展主要是由分子靶向治疗、免疫检查点抑制剂和抗血管生成药物的发展推动的，所有这些都显著改善了患者的预后，改变了这一领域的格局。本文将讨论肺癌筛查、液体活检和一线治疗中的免疫治疗的最新进展。我们讨论了最近的进展，并强调了针对具有敏感 EGFR、ALK、ROS1、RET、BRAF V600E、MET 和 NTRK 改变的 NSCLC 患者亚群的分子靶向治疗的大量新批准。
相似文献
1
Update 2020: Management of Non-Small Cell Lung Cancer.
Lung. 2020 Dec;198(6):897-907. doi: 10.1007/s00408-020-00407-5. Epub 2020 Nov 11.
2
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013.
3
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Expert Rev Respir Med. 2020 Apr;14(4):367-383. doi: 10.1080/17476348.2020.1714441. Epub 2020 Jan 17.
4
Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
Ann Transl Med. 2023 Aug 30;11(10):358. doi: 10.21037/atm-22-4444. Epub 2023 Mar 23.
5
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
Ther Adv Med Oncol. 2024 Feb 27;16:17588359231225036. doi: 10.1177/17588359231225036. eCollection 2024.
6
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
Zhonghua Zhong Liu Za Zhi. 2023 Jul 23;45(7):539-574. doi: 10.3760/cma.j.cn112152-20230510-00200.
7
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405.
8
Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Clin Lung Cancer. 2021 Jul;22(4):e519-e527. doi: 10.1016/j.cllc.2020.11.007. Epub 2020 Dec 2.
9
Biological therapies in nonsmall cell lung cancer.
Eur Respir J. 2017 Mar 2;49(3). doi: 10.1183/13993003.01520-2016. Print 2017 Mar.
10
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002891.
引用本文的文献
1
Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.
Ann Surg Oncol. 2025 Sep 7. doi: 10.1245/s10434-025-18034-w.
2
Cancer-associated mesenchymal stem cell exosomes facilitate non-small cell lung cancer cell viability and invasiveness by delivering miR-182 in a FBXW7-related AKT and ERK-dependent pathway.
Oncol Lett. 2025 Aug 19;30(4):487. doi: 10.3892/ol.2025.15233. eCollection 2025 Oct.
3
Curcumin and Resveratrol as Dual Modulators of the STAT3 Pathway in Lung Cancer: A Comprehensive Review.
Food Sci Nutr. 2025 Aug 25;13(9):e70829. doi: 10.1002/fsn3.70829. eCollection 2025 Sep.
4
Mesenchymal stem cells promote erlotinib resistance in non-small cell lung cancer through the HGF-AKT/ERK1/2-OPN pathway.
Am J Transl Res. 2025 Jul 15;17(7):4952-4963. doi: 10.62347/RKYL8675. eCollection 2025.
5
Druggable genome-wide Mendelian randomization integrating GWAS and eQTL/pQTL data identifies targets for lung squamous cell carcinoma.
Sci Rep. 2025 Aug 17;15(1):30116. doi: 10.1038/s41598-025-15977-8.
6
TFAP2A promotes NSCLC malignant progression by enhancing AOC1 transcription.
Hereditas. 2025 Aug 14;162(1):156. doi: 10.1186/s41065-025-00524-2.
7
Enhancement of anti-programmed cell death protein-1 immunotherapy in non-small cell lung cancer using arginine and citrulline supplementation.
J Thorac Dis. 2025 Jul 31;17(7):4814-4825. doi: 10.21037/jtd-2024-2109. Epub 2025 Jul 27.
8
Synergistic Effect of miR-383 and Cisplatin on Inhibition of Growth, Proliferation, and Migration of Lung Cancer Cells.
Arch Iran Med. 2025 May 1;28(5):264-274. doi: 10.34172/aim.33450.
9
Study on the mechanism of gracillin inhibiting the of lung cancer NCI-H1299 cells based on MAPK signaling pathway.
J Cancer. 2025 Jul 1;16(10):3048-3064. doi: 10.7150/jca.113694. eCollection 2025.
10
Cancer-associated fibroblasts-secreted lactate promotes RNA polymerase III subunit G-mediated epithelial-mesenchymal transition in non-small cell lung cancer by increasing m6A modification of zinc finger protein 384.
J Cell Commun Signal. 2025 Jul 25;19(3):e70037. doi: 10.1002/ccs3.70037. eCollection 2025 Sep.
本文引用的文献
1
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020.
2
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Lancet Oncol. 2020 Jul;21(7):914-922. doi: 10.1016/S1470-2045(20)30314-4. Epub 2020 Jun 12.
3
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.
N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.
4
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
6
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
7
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25.
8
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
J Thorac Oncol. 2020 Feb;15(2):288-293. doi: 10.1016/j.jtho.2019.10.002. Epub 2019 Oct 14.
9
Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice.
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21727-21731. doi: 10.1073/pnas.1911321116. Epub 2019 Oct 7.
10
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.
Zotero 插件